scholarly journals Lung cancer immunophenotypic profile: a tertiary health care institute’s experience with new WHO classification

2021 ◽  
Vol 7 (5) ◽  
pp. 266
Author(s):  
Jyoti Rajpoot ◽  
Shweta Sushmita ◽  
Charanjeet Ahluwalia ◽  
Sufian Zaheer ◽  
Rashmi Arora ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Who Classification ◽  
Squamous Carcinoma ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Immunohistochemical Examination ◽  
Invaluable Tool

<p class="abstract"><strong>Background: </strong>Lung cancer is one of the most common cancers accounting for 13% of all new cancer cases and 19% of cancer related deaths all over world. In India it constitutes 6.9% of all new cancer cases and 9.3% of all cancer related deaths in both sexes. The new 2015 WHO Classification recommends to apply immunohistochemistry, when possible, for small biopsies/cytology, and also for resected specimens.</p><p class="abstract"><strong>Methods: </strong>An observational study with 113 cases between January 2017 to January 2019 received in the department of pathology. Morphological and immunohistochemical examination was done in each case.</p><p class="abstract"><strong>Results: </strong>Based on morphology and immunohistochemistry cases were classified as adenocarcinoma, squamous cell carcinoma, adeno-squamous carcinoma, small cell carcinoma, and large cell carcinoma in accordance with 2015 WHO classification.</p><p class="abstract"><strong>Conclusions: </strong>Classification and staging of lung cancer at the time of diagnosis is the most important predictor of survival in the era of specific targeted therapy. Immunohistochemistry is proved to be an invaluable tool for definite categorization of lung cancer cases.</p>

Lung Cancer - Part I

2019 ◽  
Author(s):  
Jeffrey Crawford ◽  
John Strickler
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses both NSCLC and small cell lung cancer (SCLC), including lung cancer in those who have never smoked, prevention of lung cancer, with sections on diagnosis, biomarkers, treatment, and supportive care.  This review contains 7 figures, 10 tables, and 74 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Lung Cancer - Part I

2019 ◽  
Author(s):  
Jeffrey Crawford ◽  
John Strickler
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses both NSCLC and small cell lung cancer (SCLC), including lung cancer in those who have never smoked, prevention of lung cancer, with sections on diagnosis, biomarkers, treatment, and supportive care.  This review contains 7 figures, 10 tables, and 74 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Lung Cancer Part II

2019 ◽  
Author(s):  
Jeffrey Crawford
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses treatment of both NSCLC and small cell lung cancer (SCLC). This review 2 figures, 19 tables, and 90 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Lung Cancer Part II

2019 ◽  
Author(s):  
Jeffrey Crawford
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses treatment of both NSCLC and small cell lung cancer (SCLC). This review 2 figures, 19 tables, and 90 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.

1985 ◽  
Vol 3 (11) ◽  
pp. 1478-1485 ◽  
Author(s):  
D Osoba ◽  
J J Rusthoven ◽  
K A Turnbull ◽  
W K Evans ◽  
F A Shepherd
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Entire Group ◽  
Small Cell Lung

Fifty-three patients with recurrent and advanced stage (III and IV) non-small-cell lung cancer (NSCLC) were treated with a combination of bleomycin, etoposide (VP-16-213), and cis-diamminedichloroplatinum (BEP). Forty-eight patients were appraisable for response. The response rates were 44% for the entire group, 57% in 30 patients with combined squamous-cell and large-cell carcinoma, and 22% in 18 patients with adenocarcinoma (40%, 50%, and 19%, respectively, if patients not appraisable for response are included as nonresponders). The median survival time of patients with squamous-cell and large-cell carcinoma was slightly longer than that of patients with adenocarcinoma (23 weeks v 19 weeks). Patients with responsive disease survived significantly longer (median, 34 weeks) than did patients with unresponsive disease (median, 16 weeks) (P = .001). In the entire group, the median survival time of patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 was better (23 weeks) than of those with a status of 2 or 3 (15 weeks), but this difference was not seen in the subgroup with squamous-cell and large-cell carcinoma (24 weeks v 23 weeks, respectively). Thus, the performance status was not of prognostic value in the histologic subgroups experiencing the best response rate. There were two treatment-related deaths, but otherwise the toxicity of BEP was acceptable. Only four of the 119 treatment cycles were followed by fever even though there was significant neutropenia (0.5 X 10(9)/L) after 20 of 97 treatment cycles. The majority of patients receiving BEP experienced relief of cough, hemoptysis, pain, and fatigue associated with their disease. There was a good correlation between objective responses and palliation of symptoms. Thus, BEP offers good palliation, particularly for patients with squamous-cell and large-cell lung cancer.

Lobectomy with Bronchoplastic Procedures for Lung Cancer

1979 ◽  
Vol 65 (5) ◽  
pp. 643-648 ◽  
Author(s):  
Maurizio Valente ◽  
Cesare Grandi ◽  
Ignazio Cataldo ◽  
Giorgio Pizzocaro ◽  
Gianni Ravasi
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Carcinoma ◽  
Large Cell Carcinoma ◽  
Distant Metastases ◽  
Large Cell ◽  
Sleeve Lobectomy ◽  
Surgical Specimen ◽  
Bronchoplastic Procedures ◽  
Oat Cell Carcinoma

From April 1970 to October 1977, 19 patients with lung cancer of the upper lobar bronchus orifice underwent radical lobectomy with major bronchus resection. Sleeve lobectomy was accomplished in 11 cases and wedge lobectomy in the remaining 8. The length of the free bronchial margin in the surgical specimen was less than 1 cm in 3 cases, but limited pulmonary reserve did not allow pneumonectomy. Squamous carcinoma was diagnosed in 14 patients, adenocarcinoma in 2, oat-cell carcinoma in 2, and large cell carcinoma in one. Most cases (70%) were pathological stage I. There was one operative death due to anastomotic leakage (5%), and another patient required pneumonectomy completion. Of 13 patients with non oat-cell carcinoma and adequate bronchial resection, none had local recurrence: 3 patients developed distant metastases, and 10 are alive and disease-free after a follow-up period ranging from 16 to 104 months. The authors conclude that in selected lung cancer patients lobectomy with bronchoplastic procedures is superior to pneumonectomy for tissue sparing advantages.

scholarly journals Impact of Histopathological Diagnosis with Ancillary Immunohistochemical Studies on Lung Cancer Subtypes Incidence and Survival: A Population-Based Study

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Andrea Bordoni ◽  
Massimo Bongiovanni ◽  
Luca Mazzucchelli ◽  
Alessandra Spitale
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Incidence Rates ◽  
Small Cell ◽  
Histopathological Diagnosis ◽  
Cancer Subtypes ◽  
Immunohistochemical Studies ◽  
The Impact

Purpose. The aim of this study was to assess the impact of immunohistochemical- (IHC-) studies on incidence and survival of lung cancer histotypes.Patients and Methods. Lung cancers occurred in southern Switzerland between 1996 and 2010 were selected by the Ticino Cancer Registry and categorised into adenocarcinoma (AC), squamous-cell-carcinoma (SqCC), small-cell-carcinoma (SmCC), and large-cell carcinoma/non-small-cell lung cancer (LCC/NSCLC). Incidence rates, annual-percentage-change (APC), and two-year overall survival (OS) (follow-up: 31.12.2010) were performed.Results. 2467 cases were selected: 997 (40.4%) AC; 522 (21.2%) LCC/NSCLC, 378 (15.3%) SmCC, and 570 (23.1%) SqCC. Trend-analysis showed significant increase in AC (APC: 4.6; 95% CI: 3.1; 6.0) and decrease of LCC/NSCLC, with significant joinpoint in 2003 (APC: −14.7; 95% CI: −21.6; −7.1). Improved OS and decreased OS were detected in SqCC and LCC/NSCLC, respectively.Conclusions. This study highlights that diagnosis with ancillary immunohistochemical studies will change incidence and survival of precisely defined lung cancer subtypes. It calls attention to the need for cautious interpretation of studies and clinical trials, where the diagnosis was based on histology unaccompanied by IHC studies, and to the need of standardised diagnostic procedures.

scholarly journals Clinico-epidemiological and pathological profile of lung cancer: a hospital based observational study in Western part of Rajasthan, India

2020 ◽  
Vol 7 (6) ◽  
pp. 965
Author(s):  
C. R. Choudhary ◽  
Suresh Kumar Yogi ◽  
Gopal Purohit ◽  
Hemant Borana ◽  
Govind Desai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Surgical Techniques ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Dust Exposure ◽  
Female Ratio ◽  
Silica Dust

Background: Lung cancer is the most common cancer causing deaths in men and women world-wide, responsible for over 1 million deaths annually. Although, advances in surgical techniques and combined therapies lung cancer remains a disease with a poor prognosis. Aim of the study was to evaluate the clinico-epidemiological and pathological profile in diagnosed case of lung cancer patients, presenting in the K N Chest hospital.Methods: Initial evaluation after obtaining informed consent, demography, history, clinicoradiological findings of patients and relevant investigations was recorded. Histopathological reports reviewed.Results: Our study included 108 patients with confirmed cases of lung cancer.The mean age of the patients was 57.50 years. The male:  female ratio was 5.8:1. Cough was the most common presenting symptom (77.78%) followed by chest pain (62.33%). Clubbing was most commonly associated with squamous cell carcinoma. Most common radiological presentation was consolidation (42.59%) followed by mass lesion (30.55%). Most common histopathological type of lung cancer found in this study was squamous cell carcinoma 47(43.52%) followed by adenocarcinoma 42 (38.89%). Small cell carcinoma was present in 15 (13.89%) and large cell carcinoma was present in 4 (3.70%) study group. The most common pathological cell type in silica dust exposed patient in this study was squamous cell carcinoma followed by adenocarcinoma with occupational history of > 10 years of silica dust exposure in stone mines.Conclusions: Squamous cell carcinoma still remains the commonest histological subtype followed by adenocarcinoma.

scholarly journals Sputum cytology in bronchogenic carcinomas

1970 ◽  
Vol 39 (136) ◽  
pp. 326-328
Author(s):  
Rahjan Agrawal ◽  
Y K Jain
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Bronchogenic Carcinoma ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Sputum Cytology ◽  
Hodgkins Lymphoma ◽  
Non Hodgkins Lymphoma

Sputum cytology is an important investigation in the diagnosis of lung malignancies.The study was thus aimed at evaluating the role of sputum smears in bronchogeniccarcinomas. A total of 80 cases were included in the study. The positivity rate forvarious subtypes was squamous cell carcinoma (50%), large cell carcinoma (50%),non-hodgkins lymphoma (50%), secondaries (40%), small cell carcinoma (37.5%),hodgkins lymphoma (33.33%) and adenocarcinoma (30.77%). Peripherally locatedmalignant lesions have a reduced chance of being expectorated out in the sputum.Early morning samples are the best sample for diagnosis.It was thus concluded that Sputum cytology is important as an investigation to becarried out simultaneously with other techniques in detecting occult malignancies.KEY WORDS: Sputum Cytology, Bronchogenic Carcinoma

Sign in / Sign up

Export Citation Format

Share Document